The first PI3K/AKT/mTOR pathway inhibitors developed targeting mTORC1, everolimus and temsirolimus, are the most widely investigated mTOR inhibitors for ovarian cancer. The gene discussed is PIK3CD; the disease is ovarian carcinoma.